The Metoclopramide Black Box Warning for Tardive Dyskinesia: Effect on Clinical Practice, Adverse Event Reporting, and Prescription Drug Lawsuits
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
OBJECTIVES: We examined the effects of the black box warning about the risk of tardive dyskinesia (TD) with chronic use of metoclopramide on management of gastroparesis within a single clinical practice, and on reporting of adverse events. METHODS: Medical records of gastroparesis patients were evaluated for physician management choices. The FDA Adverse Event Reporting System (FAERS) was analyzed for event reports, and for lawyer-initiated reports, with metoclopramide from 2004 to 2010. Google Scholar was searched for court opinions against metoclopramide manufacturers. RESULTS: Before the black box warning, 69.8% of patients received metoclopramide for gastroparesis, compared with 23.7% after the warning. Gastroenterologists prescribed domperidone more often after than before the warning. Metoclopramide prescriptions decreased after 2008. Adverse event reporting increased after the warning. Only 3.6% of all FAERS reports but 70% of TD reports were filed by lawyers, suggesting a distortion in signal. Forty-seven legal opinions were identified, 33 from 2009-2010. CONCLUSIONS: The black box warning for metoclopramide has decreased its usage and increased its rate of adverse event reporting. Lawyer-initiated reports of TD hinder pharmacovigilance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Segmented regression analysis of interrupted time series studies in medication use research
Wagner, A. K., Soumerai, S. B., Zhang, F., & Ross-Degnan, D. (2002) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1046/j.1365-2710.2002.00430.x · Cited by 3,279 · cited 1×
“An interrupted time series analysis with segmented regression was performed (11), to evaluate the effect of the FDA black box warning (in February 2009) on the rate of reporting for total, neurological (defined above), and TD adverse events in comparison with the prescription usage over the same time period, using SPS…”
MethodAbell, T. L., Bernstein, V. K., Cutts, T., Farrugia, G., Forster, J., Hasler, W. L., Mccallum, R. W., Olden, K. W., Parkman, H. P., Parrish, C. R., et al. (2006) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2006.00760.x · Cited by 361 · cited 1×
“dopamine D2 receptor antagonist with peripheral effects in the gastrointestinal tract that is also used as a prokinetic agent (2) to treat gastroparesis.”
BackgroundGoodman, M. J., & Nordin, J. (2006) · PEDIATRICS · doi:10.1542/peds.2004-2687 · Cited by 65
Cited by
Correll, C. U., Detraux, J., De Lepeleire, J., & De Hert, M. (2015) · World Psychiatry · doi:10.1002/wps.20204 · Cited by 820
“medications, such as metoclopramide (275), also carry a”
BackgroundACG Clinical Guideline: Gastroparesis
Camilleri, M., Kuo, B., Nguyen, L., Vaughn, V. M., Petrey, J., Greer, K., Yadlapati, R., & Abell, T. L. (2022) · American Journal of Gastroenterology · doi:10.14309/ajg.0000000000001874 · Cited by 332
Diabetic Gastroparesis: Principles and Current Trends in Management
Krishnasamy, S., & Abell, T. L. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0454-9 · Cited by 199
“The FDA issued a black box warning in 2009 cautioning about its use beyond 3 months [111].”
BackgroundVosoughi, K., Ichkhanian, Y., Benias, P., Miller, L., Aadam, A. A., Triggs, J. R., Law, R., Hasler, W., Bowers, N., Chaves, D., et al. (2022) · Gut · doi:10.1136/gutjnl-2020-322756 · Cited by 128
Time trends in gastroparesis treatment
Dudekula, A., Rahim, S., & Bielefeldt, K. (2014) · Digestive Diseases and Sciences · doi:10.1007/s10620-014-3369-y · Cited by 21
Metadata
- Authors
- Ehrenpreis, E. D., Deepak, P., Sifuentes, H., Devi, R., Du, H., & Leikin, J. B.
- Venue
- American Journal of Gastroenterology
- Published
- 2013-06
- Volume
- 108
- Issue
- 6
- Pages
- 866-872
- ISSN
- 0002-9270 (ISSN-L)
- OpenAlex
- W2066998519
- Cited by
- 75
- References
- 3
- FWCI
- 9.79
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.